RC19D2 cell therapy for advanced large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy called RC19D2 for people with diffuse large B-cell lymphoma that has not responded to standard treatments. The therapy uses your own immune cells that are modified to target and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called diffuse large B-cell lymphoma (or a closely related type).
- Your lymphoma has not responded to at least 2 prior treatments, or has come back after a stem cell transplant.
- Your cancer cells show a protein called CD19 (your doctor can check this).
- You are at least 18 years old and in fairly good health (able to care for yourself).
- You have not had CAR-T therapy or a donor stem cell/organ transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted antibody (rituximab) before CAR T cell therapy improves outcomes for patients with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests an experimental cell therapy (RJMty19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new type of immune cell that targets two markers (CD19 and CD22) on lymphoma cells. It is for patients whose lymphoma has come back or not responded after at least two prior treatments.
Hear when a new Recurrent Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.